Butorphanol Tartrate and Zevalin

• Generic Name: butorphanol
• Dosage Forms: n.a.
• Other Brand Names: Stadol, Stadol NS

Relief of pain that is severe enough to require an opiate analgesic and for which alternative treatment options (e.g., nonopiate analgesics) have not been, or are not expected to be, adequate or tolerated.

Preoperative sedation and analgesia and as a supplement to surgical anesthesia.

Obstetric analgesia during labor.

Management of pain associated with migraine headache.

In equianalgesic doses, parenteral butorphanol is as effective as morphine, meperidine, and pentazocine, but relative potential for abuse reportedly is less than that of codeine or propoxyphene.

In symptomatic treatment of acute pain, reserve opiate analgesics for pain resulting from severe injuries, severe medical conditions, or surgical procedures, or when nonopiate alternatives for relieving pain and restoring function are expected to be ineffective or are contraindicated. Use smallest effective dosage for shortest possible duration since long-term opiate use often begins with treatment of acute pain. Optimize concomitant use of other appropriate therapies. (See Managing Opiate Therapy for Acute Pain under Dosage and Administration.)

• Generic Name: ibritumomab
• Dosage Forms: injection
• Other Brand Names: Y-90 Zevalin, In-111 Zevalin

Part of a specific therapeutic regimen (ibritumomab tiuxetan therapeutic regimen) for treatment of relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL) (designated an orphan drug by FDA for this use). Safety and efficacy not evaluated in patients with ≥25% involvement of bone marrow by lymphoma and/or impaired bone marrow reserve (e.g., prior myeloablative therapies, prior external beam radiation to >25% of active marrow, neutrophil count <1500/mm3).

Ibritumomab tiuxetan therapeutic regimen also used for consolidation treatment of newly diagnosed follicular NHL in patients who have achieved partial or complete response to first-line induction chemotherapy. Safety and efficacy not evaluated in patients with ≥25% involvement of bone marrow by lymphoma and/or impaired bone marrow reserve (e.g., prior myeloablative therapies, prior external beam radiation to >25% of active marrow, platelet count <150,000/mm3).